Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?

• Lauren A. Quinn,
• Sunaya H. Hirani,
• Thomas C. Williams,
• Ian P. Sinha

Affiliations

Lauren A. Quinn

Queens University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK

Sunaya H. Hirani

Alder Hey Children's NHS Foundation Trust, Liverpool, UK

Thomas C. Williams

Dept of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK

Ian P. Sinha

Alder Hey Children's NHS Foundation Trust, Liverpool, UK